Sonic Incytes is proud to expand its collaboration with key centers of clinical excellence in chronic liver disease in North America to continue evaluating its diagnostic solution, VelacurTM.
Indiana University (IU) has recently joined Sonic Incytes’ Early Access Program to trial VelacurTM. IU aims to evaluate VelacurTM in comparison to other methods in assessing non-alcoholic fatty liver disease (NAFLD) in 100 patients with or without advanced fibrosis, as well as other clinical indications of use.
“Velacur, developed based on meticulous research and advanced engineering, offers several advantages as a tool to assess the severity of liver disease. The small size and portability of the solution, the depth and volume of liver tissue examined and the instant results offers promise in Velacur as a potential point of care tool for evaluating patients with liver disease,” explains Dr. Samer Gawrieh, Associate Professor of Clinical Medicine and Hepatology Research Fellowship Program Director at IU. “Our human studies at IU will evaluate the performance and utility of Velacur in assessing the severity of NAFLD as well as its usefulness for evaluating patients with advanced liver disease for presence of clinically significant portal hypertension.”
In addition, further studies are underway to compare Velacur’s ability to discriminate between stages of fibrosis and steatosis. Sonic Incytes has launched new clinical trials to compare VelacurTM with MR Elastography and MRI-PDFF across all stages of fibrosis and steatosis in 100 patients with NAFLD and non-alcoholic steatohepatitis (NASH). Participating medical sites include Beth Israel Deaconess Medical Center, Southern California Research Center, Gastrointestinal Research Institute and collaboration with the UC San Diego NAFLD Research Center.
If you are a clinical center or pharmaceutical company conducting clinical research for NASH, please contact us to inquire about our Early Access Program.
ABOUT SONIC INCYTES
Sonic Incytes believes in creating accessible and affordable diagnostic solutions – with health insights you can count on – to improve patient care. Recognizing the rise of chronic liver disease, Sonic Incytes has made it its mission to reduce the disease by enabling routine assessment and improved management of liver health. Its breakthrough, point of care ultrasound solution, VelacurTM, is redefining the standard of care in quantifying chronic liver disease – with diagnostic accuracy comparable to MRI. Founded in 2017, Sonic Incytes is a health technology company headquartered in Vancouver, British Columbia, Canada.
Follow us on LinkedIn, Twitter, YouTube and www.sonicincytes.com.
